Article
The combination of gene hyperamplification and PD-L1 expression as a biomarker for the clinical benefit of tislelizumab in gastric/gastroesophageal junction adenocarcinoma.
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association - 1 Sept 2022
Lu Zhihao, Yang Silu, Luo Xuerui, Shi Yang, Lee Jong-Seok, Deva Sanjeev, Liu Tianshu, Chao Yee, Zhang Yun, Huang Ruiqi, Xu Yaling, Shen Zhirong, Shen Lin
Abstract excerpt
BACKGROUND: In solid tumor Phase 1/2 trials (NCT02407990; NCT04068519), tislelizumab demonstrated clinical benefit, including in advanced gastroesophageal adenocarcinoma (GEA). However, the majority of patients with GEA did not respond, highlighting the need to understand mechanisms of resistance and identify predictive biomarkers for response. METHODS: All tislelizumab-treated patients with GEA from the Phase...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.